Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
U. Gatzemeier(Ontario Institute for Cancer Research), Maurizio Voi(Curis (United States)), Maya Gottfried(Meir Medical Center), R. Rosso(Research Institute for Geo-Hydrological Protection), Frances A. Shepherd(University Health Network), Ronald L. Burkes(Mount Sinai Hospital), H.J.M. Groen(Martini Ziekenhuis), B. Cottier(Clatterbridge Cancer Centre NHS Foundation Trust), K. Mattson(Asklepios Fachkliniken München-Gauting), Thierry Le Chevalier(Université Grenoble Alpes), P. Weynants, H. Cortés-Funes(Centre Hospitalier René-Dubos), Maurizio Tonato
Cited by 242
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k